Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract wins round-up: LO-Q, Motive TV, Plexus ...

Thu, 11th Oct 2012 09:50

Lo-Q has announced its second contract win of the week, as an unnamed major US theme park operator has signed up to use the firm's virtual queueing system at two sites in the US. Revenue associated with the agreement is expected to scale gradually, over time. In addition, the deal grants that Lo-Q's virtual queuing systems may be extended into additional theme and water parks within the USA and globally.Motive Television keeps pace with Lo-Q, announcing its second contract award of the week as well. Mediaset, the Italian film and television giant, has renewed Motive Television's contract for another year, following the launch this week of version 3.0 of the London firm's patented broadcast video-on-demand solution.Completing a hat-trick of companies that announced contract wins on both Tuesday and Thursday of this week is oil and gas engineering services business, Plexus, which has secured a £1m contract to supply its POS-GRIP technology well-head equipment to Lotos Exploration & Production Norge, a new customer for Plexus. The contract is for a two year period and can be extended for an additional year. Revenues are due to commence November 2012.ValiRx, a life science company focused on cancer diagnostics, has entered into a UK distribution agreement with First Health Products for the distribution and sale of ValiRx's SELFCheck health screening products in the UK. The agreement, which is initially for a period of five years, means that the company will no longer incur any of the direct expenses or management time associated with the sales and marketing campaigns of SELFCheck products in the UK. ValiRx will continue to benefit from an income stream from the royalty payments made to the company from UK sales.Speech recognition software specialist Eckoh has had its contract with cinema operator Vue Entertainment renewed for another three years. Eckoh supplies the technology which provides cinema listings information and ticket booking options over the phone. The contract, which runs until October 2015, has also made provision to include social media monitoring and broader customer interaction that will make additional use of Eckoh's multi-channel service capability. JH
More News
2 Nov 2021 09:57

AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts

AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts

Read more
16 Sep 2021 18:19

IN BRIEF: ValiRx inks evaluation agreement for breast cancer treatment

IN BRIEF: ValiRx inks evaluation agreement for breast cancer treatment

Read more
7 Sep 2021 15:05

EARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips

EARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips

Read more
6 Jul 2021 13:00

ValiRx adds three new patents in first half

(Sharecast News) - Clinical-stage drug development company ValiRx updated the market on its patent portfolio on Tuesday, reporting that it had continued to build its intellectual property position in the first half of the year.

Read more
27 May 2021 20:17

TRADING UPDATES: Brave Bison, Strix Group see strong performances

TRADING UPDATES: Brave Bison, Strix Group see strong performances

Read more
27 May 2021 13:54

ValiRx terminates peptide drug candidate deal

(Sharecast News) - Clinical-stage drug development company ValiRx announced on Thursday that it has ended its agreement over the evaluation of the 'KTH222' peptide as a drug candidate for treating patients with ovarian cancer.

Read more
20 May 2021 16:07

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
28 Apr 2021 15:30

EXECUTIVE CHANGES: Ex-Coca-Cola exec, Cafe Rouge founder for Deliveroo

EXECUTIVE CHANGES: Ex-Coca-Cola exec, Cafe Rouge founder for Deliveroo

Read more
27 Apr 2021 11:32

TRADING UPDATES: Focusrite sales soar; Gaming Realms in Slingo boost

TRADING UPDATES: Focusrite sales soar; Gaming Realms in Slingo boost

Read more
15 Feb 2021 16:04

Physiomics and ValiRx enter new collaboration deal

(Sharecast News) - Oncology consulting company Physiomics has entered into a new agreement with clinical-stage drug development company ValiRx, it announced on Monday, superseding the agreement between the two companies, which was announced in September 2011.

Read more
15 Feb 2021 11:05

IN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics

IN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics

Read more
19 Jan 2021 16:53

IN BRIEF: ValiRx's VAL201 Patented For Treatment Of Metastatic Cancer

IN BRIEF: ValiRx's VAL201 Patented For Treatment Of Metastatic Cancer

Read more
10 Nov 2020 17:40

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

Read more
23 Sep 2020 19:09

UK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges

UK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges

Read more
7 Sep 2020 11:55

ValiRx Loss Narrows In First Half Amid Reduction In Expenses

ValiRx Loss Narrows In First Half Amid Reduction In Expenses

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.